[Usefulness of bilateral sympathectomy using video-assisted thorascopic surgery in the treatment of essential hyperhidrosis].
Essential, idiopathic, or primary hyperhidrosis is defined as excessive sweating in certain areas of the body due to factors unrelated to other disease. Clinical presentation can be categorized as palmar, plantar, axillary, or craniofacial. Medical treatment (aluminium salts, iontophoresis, anticholinergic drugs, and alpha2-agonists) is of questionable effectiveness. Intradermal injections of botulinum toxin are very effective for the treatment of axillary hyperhidrosis. Surgical treatment involves resection (sympathectomy) or electrocautery (sympathicolysis) of the thoracic sympathetic chain, or compression of the sympathetic chain with clips, in all cases via video-assisted thorascopic surgery. One or more ganglia between T2 and T5 are usually resected depending on the area affected by hyperhidrosis: T2 for craniofacial hyperhidrosis, T3 and T4 for palmar hyperhidrosis, and T3 to T5 for combined palmar and axillary hyperhidrosis. The technique is very useful and is effective in those patients with primary hyperhidrosis who have not responded to conservative treatment.
García-Franco
C E
CE
Departamento de Cirugía Torácica. Clínica Universitaria de Navarra (CUN). Pamplona. España. cegarciaf@unav.es
España
A
A
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D017607:Aluminum Compounds; D001365:Axilla / Q000294:innervation; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003250:Constriction; D004564:Electrocoagulation; D005145:Face / Q000294:innervation; D005728:Ganglia, Sympathetic / Q000601:surgery; D015171:Ganglionectomy / Q000379:methods; D006225:Hand / Q000294:innervation; D006801:Humans; D006945:Hyperhidrosis / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D007478:Iontophoresis; D013562:Sympathectomy / Q000379:methods*; D020775:Thoracic Surgery, Video-Assisted; D013904:Thoracic Vertebrae; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D017607:Aluminum Compounds; D018680:Cholinergic Antagonists; D019274:Botulinum Toxins, Type A